Eosinophilic Asthma Market Report 2026

Eosinophilic Asthma Market Overview

• Eosinophilic Asthma market size has reached to $3.16 billion in 2025 • Expected to grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 16.9% • Growth Driver: Impact Of Rising Smoking Habits On The Growth Of The Market • Market Trend: Advancements In Targeted Therapies For Severe Asthma Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Eosinophilic Asthma Market?

Eosinophilic asthma is a form of asthma where high eosinophil counts, a specific white blood cell type, cause airway inflammation. This condition results in severe symptoms such as breathing issues and recurring flare-ups, with limited effectiveness from standard treatments such as inhaled steroids. The main diseases types in the eosinophilic asthma are severe eosinophilic asthma and mild to moderate eosinophilic asthma. Severe eosinophilic asthma is a severe variant of asthma marked by elevated levels of eosinophils, a type of white blood cell that plays a role in airway inflammation. Treatment options include biologics, bronchodilators, corticosteroids, immunomodulators, and other therapies. These treatments are used in hospitals, clinics, and other healthcare settings.

What Is The Eosinophilic Asthma Market Growth Forecast?

The eosinophilic asthma market size is expected to see rapid growth in the next few years. It will grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to precision asthma treatment growth, biologic drug pipeline expansion, biomarker-based diagnosis, personalized respiratory care, specialty clinic expansion. Major trends in the forecast period include growing adoption of biologic therapies, increased focus on severe asthma phenotypes, rising demand for targeted immunotherapy, expansion of specialized respiratory clinics, emphasis on reducing exacerbation rates.

What Is The Driver Of The Eosinophilic Asthma Market?

The rising smoking habits are expected to propel the growth of the eosinophilic asthma market going forward. Smoking habits refer to the regular behaviors or patterns of using tobacco products, such as the frequency, context, and duration of smoking, often influenced by psychological, social, and environmental factors. The rising smoking habits are due to factors such as increased stress levels, targeted marketing by tobacco companies, lack of awareness about health risks, and social acceptance of smoking in certain cultures. Eosinophilic asthma treatment helps reduce airway inflammation and improve lung function, which can encourage smoking cessation by alleviating the respiratory issues that often drive patients to continue smoking. For instance, in November 2025, according to the Office for National Statistics, a UK-based government agency, the percentage of women who reported using e-cigarettes in Great Britain increased from 8.5% in 2023 to 10.0% in 2024. Further, daily e-cigarette use was highest among people aged 25 to 34 years and 35 to 49 years in Great Britain (9.3% and 9.5%, respectively) and has increased among both age groups from 2023. Therefore, the rising smoking rates is driving the eosinophilic asthma industry.

Key Players In The Global Eosinophilic Asthma Market

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

Global Eosinophilic Asthma Market Trends and Insights

Major companies operating in the eosinophilic asthma market are developing innovative drugs to target specific immune pathways, reduce inflammation, and improve patient outcomes through personalized treatment options. A monoclonal antibody is a type of laboratory-made molecule that can mimic the immune system's ability to fight off harmful pathogens such as viruses and bacteria that are created through a process involving the fusion of a specific antibody-producing cell with a cancer cell, allowing the production of large quantities of identical antibodies. For instance, in August 2024, AstraZeneca plc, a UK-based biopharmaceutical company, announced Fasenra was approved by China's National Medical Products Association, a China-based government agency, for the treatment of severe eosinophilic asthma. It is specifically indicated for patients with severe eosinophilic asthma, a condition characterized by high levels of eosinophils, which can lead to inflammation and worsening asthma symptoms. It is a monoclonal antibody that targets and depletes eosinophils through a unique mechanism. Fasenra enhances the immune system's ability by binding to the IL-5 receptor on eosinophils to reduce eosinophil levels in the blood and tissues. The dosing regimen involves an initial loading phase followed by maintenance doses. Patients usually receive injections every four weeks for the first three doses, followed by every eight weeks thereafter.

What Are Latest Mergers And Acquisitions In The Eosinophilic Asthma Market?

In February 2024, GSK plc, a UK-based biopharmaceutical company, acquired Aiolos Bio for $1 billion. With this acquisition, GSK aims to boost its respiratory portfolio by targeting severe asthma patients with low T2 inflammation and expand its market reach and leadership in respiratory therapies while addressing a broader spectrum of asthma patients. Aiolos Bio is a US-based biotechnology company that specializes in developing treatments for respiratory and inflammatory conditions, including eosinophilic asthma.

What Defines the Eosinophilic Asthma Market?

The eosinophilic asthma market consists of sales of mepolizuma and benralizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Eosinophilic Asthma Market Report 2026?

The eosinophilic asthma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the eosinophilic asthma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.